Puma Biotechnology Inc (PBYI): Price and Financial Metrics


Puma Biotechnology Inc (PBYI): $4.26

0.02 (+0.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PBYI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PBYI POWR Grades

  • Value is the dimension where PBYI ranks best; there it ranks ahead of 97.86% of US stocks.
  • The strongest trend for PBYI is in Quality, which has been heading up over the past 177 days.
  • PBYI ranks lowest in Momentum; there it ranks in the 5th percentile.

PBYI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PBYI is 9.83 -- better than 96.59% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 17.59 for PUMA BIOTECHNOLOGY INC; that's greater than it is for 97.54% of US stocks.
  • Over the past twelve months, PBYI has reported earnings growth of -161.97%, putting it ahead of only 9.7% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to PUMA BIOTECHNOLOGY INC, a group of peers worth examining would be EXTR, ARAY, NTAP, IQ, and JAGX.
  • PBYI's SEC filings can be seen here. And to visit PUMA BIOTECHNOLOGY INC's official web site, go to www.pumabiotechnology.com.

PBYI Valuation Summary

  • PBYI's EV/EBIT ratio is 11.2; this is 13.13% higher than that of the median Healthcare stock.
  • PBYI's price/earnings ratio has moved up 47.7 over the prior 131 months.

Below are key valuation metrics over time for PBYI.

Stock Date P/S P/B P/E EV/EBIT
PBYI 2023-01-20 0.9 9.0 20.3 11.2
PBYI 2023-01-19 0.9 8.8 19.9 10.9
PBYI 2023-01-18 0.9 9.1 20.5 11.2
PBYI 2023-01-17 1.0 9.5 21.4 11.6
PBYI 2023-01-13 1.0 9.9 22.4 12.1
PBYI 2023-01-12 1.0 9.7 21.8 11.8

PBYI Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -181.24%.
  • Its 4 year cash and equivalents growth rate is now at -15.69%.
  • The 2 year cash and equivalents growth rate now stands at -30.71%.
Over the past 33 months, PBYI's revenue has gone down $54,547,000.

The table below shows PBYI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 217.713 -28.945 9.832
2022-06-30 206.856 -35.706 -34.48
2022-03-31 200.722 -21.906 -48.957
2021-12-31 253.155 20.65 -29.126
2021-09-30 250.355 20.45 -48.244
2021-06-30 254.864 11.672 -35.035

PBYI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PBYI has a Quality Grade of C, ranking ahead of 66.91% of graded US stocks.
  • PBYI's asset turnover comes in at 1.012 -- ranking 23rd of 682 Pharmaceutical Products stocks.
  • ACAD, TVTX, and CTMX are the stocks whose asset turnover ratios are most correlated with PBYI.

The table below shows PBYI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.012 0.749 -0.448
2021-06-30 0.995 0.755 -0.266
2021-03-31 1.058 0.780 -0.137
2020-12-31 0.905 0.825 -0.449
2020-09-30 0.955 0.836 -0.355
2020-06-30 1.008 0.842 -0.212

PBYI Price Target

For more insight on analysts targets of PBYI, see our PBYI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.63 Average Broker Recommendation 2.06 (Hold)

PBYI Stock Price Chart Interactive Chart >

Price chart for PBYI

PBYI Price/Volume Stats

Current price $4.26 52-week high $5.16
Prev. close $4.24 52-week low $1.60
Day low $4.12 Volume 194,036
Day high $4.30 Avg. volume 327,112
50-day MA $4.45 Dividend yield N/A
200-day MA $3.10 Market Cap 194.43M

Puma Biotechnology Inc (PBYI) Company Bio


Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.


PBYI Latest News Stream


Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream


Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Puma Biotechnology's (NASDAQ:PBYI) investors will be pleased with their decent 96% return over the last year

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...

Yahoo | January 25, 2023

Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference

LOS ANGELES, January 12, 2023--Alan Auerbach will provide a corporate overview of Puma Biotechnology at B. Riley Securities' Annual Oncology Conference on Jan. 19 at 11:00 a.m. PST.

Yahoo | January 12, 2023

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, January 11, 2023--Puma Biotechnology announced the grant of inducement awards to four new non-executive employees, as required by Nasdaq Listing Rule 5635(c)(4).

Yahoo | January 11, 2023

Puma Biotechnology Releases Updated Corporate Presentation

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released an updated corporate presentation that will be used in investor meetings in the coming weeks.

Business Wire | January 9, 2023

Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals

Puma Biotechnology recently bounced from its November lows, rallying from $2 to $5.16 in a matter of weeks. Click here to read my valuation analysis of PBYI stock.

Seeking Alpha | December 27, 2022

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo 0.71%
3-mo 89.33%
6-mo 36.98%
1-year 86.84%
3-year -45.80%
5-year -93.63%
YTD 0.71%
2022 39.14%
2021 -70.37%
2020 17.26%
2019 -57.00%
2018 -79.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 19.6177 seconds.